Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology Jg. 30; H. 18; S. 2183
Hauptverfasser:	Younes, Anas, Gopal, Ajay K, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Ramchandren, Radhakrishnan, Bartlett, Nancy L, Cheson, Bruce D, de Vos, Sven, Forero-Torres, Andres, Moskowitz, Craig H, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Kennedy, Dana A, Sievers, Eric L, Chen, Robert
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 20.06.2012
Schlagworte:	Adolescent Adult Aged Antineoplastic Agents - therapeutic use Disease-Free Survival Female Hodgkin Disease - drug therapy Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Male Middle Aged Recurrence Young Adult
ISSN:	1527-7755, 1527-7755
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!